Does spironolactone ameliorate trastuzumab-induced cardiac toxicity?

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 231-234

  Yavas, Guler ^a   Elsurer, Rengin ^a   Yavas, Cagdas ^b   Elsurer, Cagdas ^a   Ata, Ozlem ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b KONYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERFORMANCE ENHANCING SUBSTANCE; SPIRONOLACTONE; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER PROGNOSIS; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; DRUG CYTOTOXICITY; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENOME; HEART INJURY; HEART MITOCHONDRION; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR PATHOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PROTO ONCOGENE; TRANSACTIVATION; UPREGULATION; UROGENITAL SYSTEM;

ANTIBODIES, MONOCLONAL, HUMANIZED; HEART; HUMANS; SPIRONOLACTONE;

EID: 84880036281     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.042     Document Type: Article

References (37)

1. Benz C.C., O'Hagen R.C., Richter B., et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997, 15:1513-1525.
2. Wonders K.Y., Reigie B.S. Trastuzumab and doxorubicin related cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther 2009, 8:17-21.
3. Albanell J., Bellmunt J., Moline R., et al. Node negative breast cancers with p53 (-)/HER2-neu status may identify women with very good prognosis. Anticancer Res 1996, 16:1027-1032.
4. Romond E.H., Perez E.A., Bryan J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005, 353:1673-1684.
5. Perez E.A., Suman V.J., Davidson N. et al. NCCTG N9831, May 2005 update Presented at the 45th annual meeting of the American Society of Clinical Oncology Orlando FL, May 16, 2005.
6. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial. Lancet 2007, 369:29-36.
7. Joensuu H., Kellokumpu-Lehtienen P.L., Bono P., et al. Adjuvant docetaxel or vineralbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
8. Halyard M.Y., Pisansky T.M., Dueck A.C., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 2009, 27(16):2638-2644.
9. Vogel C., Cobleigh M.A., Triphaty D.A., et al. Adjuvant docetaxel or vineralbine with or without trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 2001, 344:783-792.
11. Leyland Jones B., Gelmon K., Ayoub J.P., et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003, 21:3965-3971.
12. Seiman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the Trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221.
13. Sengupta P.P., Northfelt D.W., Gentile F., Zamorano J.L., Khandheria B.K. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008, 83(2):197-203.
14. Chen K.R. Myocyte survival pathways and cardiomyopathy: implications for Trastuzumab cardiotoxicity. Semin Oncol 2000, 28:20-27.
15. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
16. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
17. Dorrance A.M., Osborn H.L., Grekin R., Webb R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001, 281:R944-950.
18. Florian J.A., Dorrance A., Webb R.C., Watts S.W. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am J Physiol Regul Integr Comp Physiol 2001, 281:R878-886.
19. Nakano S., Kobayashi N., Yoshida K., Ohno T., Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extyracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005, 28:925-936.
20. Fiebeler A., Nussenberger J., Shagdarsuren E., et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
21. Krug A.W., Grossmann C., Schuster C., et al. Aldosterone stimulates epidermal growth factor receptor (EGFR) expresssion. J Biol Chem 2003, 278:43060-43066.
22. Lee K.F., Simon H., Chen H., et al. Requirement for neureguli receptor erbB2 in neural and cardiac development. Nature 1995, 378-394.
23. Erickson S.L., O'Shea K.S., Ghabossi N., et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997, 124:4999.
24. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the perevention of dilated cardiomyopathy. Nat Med 2002, 8:459.
25. Perik P.J., de Vries E.G., Gietema J.A., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007, 9:173.
26. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Cin Oncol 2005, 23(31):7820-7826.
27. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience. J Clin Oncol 2006, 24(25):4107-4115.
28. Grossmann C., Gekle M. Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Streoids 2008, 73:973-978.
29. Asakura M., Ktakaze M., Takashima S., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002, 8:35-40.
30. Prensel N., Zwick E., Daub H., et al. EGF-receptor transactivation by G-protein-coupled receptors requires metalloprotesae cleavage of proHB-EGF. Nature 1999, 402:884-888.
31. Zhand H., Chalothorn D., Jackson L.F., Lee D.C., Faber J.E. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 2004, 95:989-997.
32. Voisin L., Foisy S., Giasson E., Lambert C., Moreau P., Meloche S. EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. AJP-Cell Physiol 2002, 283:C446-55.
33. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induced cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000, 97:931-936.
34. Ng R., Better N., Green M.D. Anticancer agents and cardiotoxicity. Semin Oncol 2006, 33(1):2-14.
35. Telli M.L., Hunt S.A., Carlson R.W., Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25(23):3525-3533.
36. Feldman A.M., Lorell B.H., Reis S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000, 102(3):272-274.
37. Moy B., Kirkpatrick P., Kar S., Goss P. Lapatinib. Nat Rev Drug Discov 2007, 6(6):431-432.